Weiwei Tan

9.0k citations
58 papers · 2.0k · 1 hit paper · h-index 20

Impact in

Papers in

    • Lung Cancer Treatments and Mutations 30
    • Advanced Breast Cancer Therapies 5
    • Colorectal Cancer Treatments and Studies 13
    • HER2/EGFR in Cancer Research 7
    • Lung Cancer Research Studies 5

Weiwei Tan

55 papers receiving 1.9k citations

Weiwei Tan's Hit Papers

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib 2011 · 487 citations
4870+5+10Years since publication100200300400

Peers

Weiwei Tan
Comparison fields: 5 of 82
  • Pulmonary and Respiratory Medicine 1.1k
  • Oncology 790
  • Hepatology 103
  • Cancer Research 179
  • Molecular Biology 729
Replace Peter Stopfer with:
Peter Stopfer Germany
A. Benjamin Suttle United States
Kun He China
Heike Richly Germany
Chenghua Xia United States
Roger Keresztes United States
Debashis Sarker United Kingdom
Marie-Christine Étienne-Grimaldi France
Tetsuhiko Shirasaka Japan
Philip J. Gold United States
Weiwei Tan relative to Peter Stopfer Germany Peter Stopfer's profile →
Citations per field
00.5×1.5×
Peter Stopfer · 1×
Citations per year

Countries citing papers authored by Weiwei Tan

Since Specialization
Citations

This map shows the geographic impact of Weiwei Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Tan more than expected).

Fields of papers citing papers by Weiwei Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiwei Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Tan. The network helps show where Weiwei Tan may publish in the future.

Co-authors

The 25 scholars most cited alongside Weiwei Tan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Weiwei Tan Line = papers co-authored together Weiwei Tan links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.

#Work
1
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Hit paper breakdown →
2011487
2 2011351
3 2010208
4 2012106
5 201049
6 201447
7 201545
8 201745
9 201641
10 201041
11 201437
12 201137
13 200534
14 201932
15 202227
16 201527
17 201926
18 202122
19 201621
20 201821

About Weiwei Tan

Weiwei Tan is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Epidemiology, having authored 58 papers that have together received 2.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (30 papers), Colorectal Cancer Treatments and Studies (13 papers), HER2/EGFR in Cancer Research (7 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Advanced Breast Cancer Therapies (5 papers), Lung Cancer Research Studies (5 papers), Protein Degradation and Inhibitors (4 papers) and Melanoma and MAPK Pathways (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.1k citations), Oncology (790 citations), Hepatology (103 citations), Cancer Research (179 citations) and Molecular Biology (729 citations). Weiwei Tan has collaborated with scholars based in United States, China and Italy. Frequent co-authors include Keith D. Wilner, Zhongzhou Shen, Susumu Kobayashi, Wee-Lee Yeo, Shuchi S. Pandya, Daniel B. Costa, Benjamin Solomon, D. Ross Camidge, Sai‐Hong Ignatius Ou and Ravi Salgia. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Future Oncology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact